en · de · es · fr · pt
bpc-157-notes.peptides9000.com › Data › Background, Origin, And Naming — Field Notes

Background, Origin, And Naming — Field Notes

By Editorial Desk · published 2025-07-17 · last reviewed 2025-08-21 · Data

peptide content comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.

Updated 2025-08-21. Numbers and descriptions here follow the published literature rather than marketing material.

Background, Origin, and Naming

BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.

Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.

Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.

Storage, Solubility, And Analysis

Lyophilized material is generally kept cold, commonly at minus twenty degrees Celsius, and shielded from moisture and light. Solutions are less stable than the dry powder, so repeated freeze-thaw cycles are avoided by splitting the material into single-use portions. Published stability data for this particular peptide are limited, which means suggested hold times should be read as provisional. Long-term refrigeration of reconstituted solutions is not well supported by available evidence.

Identity and purity are checked with standard peptide techniques. Reversed-phase high-performance liquid chromatography separates the main peak from closely related impurities and yields a percentage purity. Mass spectrometry confirms that the measured mass matches the theoretical value. Amino acid analysis offers an independent check on overall composition. These analytical methods characterize the material itself and reveal nothing about how it behaves in a living system.

Bpc-157 at a glance

PropertyValueNotes
Molecular formulaC62H98N16O22Computed for the free peptide
Monoisotopic massApproximately 1419 DaReported values shift with counterion and hydration
Residue count15 amino acidsSequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
OriginFragment of human gastric juice proteinFirst described in early 1990s research reports
Common synonymsBPC 157; PL 14736; bepecinNaming varies across papers and catalogues

Analysis, Stability, and Handling

Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated sequences and other synthesis by-products. Mass spectrometry, typically electrospray ionization coupled to liquid chromatography, confirms the expected mass and helps detect modifications. Amino acid analysis can verify composition when residue-level confirmation is needed. Because common impurities differ from the target by only one or two residues, chromatographic resolution often matters more than a single headline purity percentage. Impurity profiles are most informative when compared against a validated reference standard.

Lyophilized material is generally reported as stable for extended periods when kept cold, dry, and protected from light. In solution, the main degradation routes for a peptide of this type are hydrolysis of peptide bonds and aggregation. The sequence contains no cysteine, so disulfide-driven oxidation is not a primary concern, though methionine and tryptophan are also absent. Stability depends on pH, buffer composition, and concentration, with acidic conditions often reported as more favorable than neutral or alkaline ones. Repeated freeze-thaw cycles can promote aggregation, and how fast degradation proceeds at room temperature in specific formulations remains an open question.

Handling practice centers on limiting moisture, heat, and mechanical stress. Powder is typically allowed to reach room temperature before opening so that condensation does not form on the contents, and solutions are prepared with sterile or low-particulate water. Peptides can adsorb to certain plastics and membrane filters, so container and filter material is sometimes specified to reduce losses at low concentrations. Working aliquots are usually frozen separately rather than sampled repeatedly from one stock. Recording lot number, preparation date, and storage conditions supports later comparison between experiments.

Related pages on this site

Origin and Peptide Identity

Supplied material is typically a lyophilized white to off-white powder. The peptide is freely soluble in water and in common aqueous buffers, which allows it to be handled as a stock solution. Because the sequence contains no cysteine, disulfide cross-linking is not a route of degradation. The absence of aromatic residues means ultraviolet absorbance at 280 nm is minimal, so quantification usually relies on peptide bond absorbance near 214 nm or on amino acid analysis.

Common synonyms in catalogs include pentadecapeptide BPC 157, BPC157, and the full sequence name. A CAS registry number in the 137525-51-0 range is frequently listed, though the assignment should be verified against the supplier certificate of analysis. The name itself is not a pharmacopoeial designation, and there is no standardized international nonproprietary name. Distinguishing genuine material from related fragments generally requires mass spectrometry, since several truncated sequences share similar chromatographic behavior.

BPC-157 is a synthetic pentadecapeptide whose sequence is commonly given as Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is described in the literature as a fragment of a larger protein found in human gastric juice, referred to as body protection compound. The peptide was first characterized in the early 1990s by a research group in Zagreb, Croatia. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.

Handling, Storage, and Quality Control

In its usual supplied form, the peptide is a white to off-white lyophilized powder that dissolves readily in water and in aqueous buffers. Powder keeps far longer than solution, so material is normally shipped and stored dry, then dissolved only when needed. Once in solution, the chain is subject to hydrolysis and the liquid supports microbial growth, and practical guidance generally treats the dissolved form as short-lived. Containers should stay sealed and desiccated, because the powder takes up moisture from air.

Long-term storage of the dry powder is typically described at minus twenty degrees Celsius or colder, while shorter holding periods may use ordinary refrigeration. Repeated warming and cooling cycles are discouraged because they stress the material and can promote aggregation or loss. Light exposure and residual moisture are both treated as avoidable sources of degradation, and working aliquots are often prepared to limit how many times a container is opened. Sealed vials with a desiccant are the usual container.

Quality assessment rests on two separate questions: whether the chain is the intended one, and how much of the sample is that chain. Reverse-phase high-performance liquid chromatography with ultraviolet detection is the standard purity measurement, while mass spectrometry confirms identity through the observed molecular mass. Amino acid analysis and sequence verification provide further checks. A reported purity percentage describes the proportion of the sample represented by the main peak, not the amount of peptide by mass, since counter-ions and water make up part of any lyophilized lot.

Further detail

=== Nonsense mutations === Nearly 11% of all inherited genetic disorders are caused by premature stop codon (nonsense mutations). Notable examples of nonsense mutations that have received extensive research are the CFTR, which causes cystic fibrosis, and dystrophin mutations, which causes Duchenne muscular dystrophy. Recent therapeutic research has focused on forcing readthrough of premature stop codons. This would allow the previously mutated mRNA strand to potentially code for a correctly folded protein. A common method of forcing readthrough is to limit the activity of eRF1 and eRF3. One mechanism proposed limiting the concentrations of eRF1 and eRF3 in the cells, which would theoretically reduce stop codon recognition. However, this mechanism has not been used in therapeutic remedies. Instead the most promising mechanism involves chemical degradation of eRF1 to achieve readthrough. These chemicals are under the branch of drugs called readthrough promoters. The mechanism of readthrough promoters vary, however a common mechanism is to prevent eRF1 from releasing out of the ribosome. This results in a stalled ribosome then finally a collision with another ribosome.

nylon-flock workers workers who spray prints onto textiles with polyamide-amine dyes battery workers who are exposed to thionyl chloride workers at plants that use or manufacture diacetyl Diacetyl is a chemical used to produce the artificial butter flavoring in many foods such as candy and microwave popcorn and occurring naturally in wines. This first came to public attention when eight former employees of the Gilster-Mary Lee popcorn plant in Jasper, Missouri developed bronchiolitis obliterans. Due to this event, bronchiolitis obliterans began to be referred to in the popular media as "popcorn lung" or "popcorn workers lung". It is also referred to as "flavorings-related lung disease".

For an intravenously administered drug, the bioavailability F will equal 1, since the drug is directly introduced to the bloodstream. If the patient requires an oral dose, bioavailability will be less than 1 (depending upon absorption, first pass metabolism etc.), requiring a larger loading dose.

=== Organic synthesis === Acetonitrile is a common two-carbon building block in organic synthesis of many useful chemicals, including acetamidine hydrochloride, thiamine, and 1-naphthaleneacetic acid, along with more complex nitriles. Its reaction with cyanogen chloride affords malononitrile.

Sources: en.wikipedia.org

Supporting material

== Before 1947 == "Indian", which has been used as an alternative for the Indigenous peoples of the Americas, originated with Christopher Columbus, who, in his search for India, thought that he had arrived in the East Indies. This historical misnomer has persisted over the centuries, shaping cultural perceptions and narratives surrounding Native American identity.

Arsenic trioxide (ATO) (Latin: Arsenum trioxydatum) is used as a chemotherapeutic agent in the treatment of acute promyelocytic leukemia (APL). It was approved for medical use in the United States in 2000. Arsenic trioxide is also included on the World Health Organization's List of Essential Medicines. Despite its therapeutic use, arsenic trioxide is highly toxic and has historically caused numerous cases of acute and chronic arsenic poisoning. It is classified as an orphan drug and is marketed under the brand name Trisenox. When dissolved in water, it forms arsenous acid. Arsenic trioxide inhibits the proliferation of cancer cells and promotes their differentiation or apoptosis, although its precise mechanism of action remains incompletely understood. Because of its toxicity, arsenic has been used for centuries as a potent poison. Its anticancer properties were recognized in the 20th century, but early efforts to administer it orally were ineffective. Therapeutic benefits were observed only with intravenous administration, particularly in treating the rare cancer acute promyelocytic leukemia. Initially, arsenic trioxide was used to treat APL only after standard retinoid and chemotherapy regimens had failed. However, it is now commonly used as first-line therapy in combination with tretinoin (ATRA) for patients with non-high-risk APL, rather than solely as salvage therapy following relapse. The treatment is generally well tolerated and associated with relatively few side effects. Ongoing research is investigating additional therapeutic applications for this drug.

== Clinical significance == There is an age-dependent decline in the synthesis of keratan sulfate chains, so non-glycated forms of fibromodulin can accumulate in tissues such as cartilage. Fibromodulin is found in the epidermis of human skin and is expressed by skin cells (keratinocytes) in culture. Mice with the gene for fibromodulin knocked out (Fmod-/-) have very fragile skin and abnormal tail and Achilles tendons. The collagen fiber bundles in these tendons are fewer and disorganised and there is less endotenon surrounding the tendon tissue. The levels of lumican, a SLRP with one of the same collagen binding sites as fibromodulin, is increased 4 fold in the tail tendons of Fmod-knockout mice.

Sources: en.wikipedia.org

Supporting material

input from rivers sulfate reduction and sulfide re-oxidation on continental shelves and slopes burial of anhydrite and pyrite in the oceanic crust. The primary natural source of sulfur to the atmosphere is sea spray or windblown sulfur-rich dust, neither of which is long lived in the atmosphere. In recent times, the large annual input of sulfur from the burning of coal and other fossil fuels has added a substantial amount of SO2 which acts as an air pollutant. In the geologic past, igneous intrusions into coal measures have caused large scale burning of these measures, and consequential release of sulfur to the atmosphere. This has led to substantial disruption to the climate system, and is one of the proposed causes of the Permian–Triassic extinction event. Dimethylsulfide [(CH3)2S or DMS] is produced by the decomposition of dimethylsulfoniopropionate (DMSP) from dying phytoplankton cells in the ocean's photic zone, and is the major biogenic gas emitted from the sea, where it is responsible for the distinctive “smell of the sea” along coastlines. DMS is the largest natural source of sulfur gas, but still only has a residence time of about one day in the atmosphere and a majority of it is redeposited in the oceans rather than making it to land. However, it is a significant factor in the climate system, as it is involved in the formation of clouds.

Antimony-125 decays with a half-life of over two years to 125mTe which itself decays with a half-life of almost two months via isomeric transition to the ground state. While its relatively short half-life and the significant gamma emissions (144.77 keV) of its daughter nuclide make usage in an RTG less attractive, Sb-125 could deliver a relatively high power density of 3.4 Wthermal/g. Fluoride volatility can recover antimony as the mildly volatile (solid at room temperature) antimony trifluoride or the more volatile (boiling point 422.6 K (149.5 °C; 301.0 °F)) antimony pentafluoride.

== Effect of molecular weight == At constant pressure and temperature, the root-mean-square speed and therefore the effusion rate are inversely proportional to the square root of the molecular weight. Gases with a lower molecular weight effuse more rapidly than gases with a higher molecular weight, so that the number of lighter molecules passing through the hole per unit time is greater.

In 1947, Howard Hughes redirected the Hughes Aircraft Company's efforts from airplanes to helicopters. The effort began in earnest in 1948, when helicopter manufacturer Kellett Autogiro Corporation sold their latest design to Hughes for production. The XH-17 "Sky Crane" first flew in October 1952, but was commercially unsuccessful. In 1955 the company began building light helicopters when Howard Hughes split the helicopter production unit from the Hughes Aircraft Co., and reconstituted it with the Hughes Tool Co. as the Hughes Tool Co. Aircraft Division, with a focus on the production of light helicopters. The Hughes Model 269 was the company's first successful helicopter design. Built in 1956, and entering production in 1957, it served to capture a large portion of the commercial market for Hughes. It would eventually become part of the Army inventory as a primary trainer (TH-55 Osage). In May 1965, the company won the contract for a new observation helicopter for the U.S. Army, and produced the OH-6 Cayuse (Hughes Model 369). The OH-6 was later developed into the civilian Model 500, variants of which remain in production to this day.

Sources: en.wikipedia.org

Frequently asked questions

What is BPC-157?

BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence corresponds to a fragment of a protein found in human gastric juice. It is studied mainly in preclinical research and is not an approved pharmaceutical product in major markets. Materials sold for laboratory use are typically labelled as research chemicals.

Is BPC-157 approved for medical use?

No medicines regulator in the United States or the European Union has approved BPC-157 as a therapeutic product. Presenting it as a drug or as a dietary supplement ingredient would generally not match its regulatory status. Availability as a research chemical does not imply clinical approval.

Why is the literature on BPC-157 considered preliminary?

Published reports rest largely on animal models and cell culture rather than controlled human trials. Review articles describe the proposed mechanisms as incompletely understood. Conclusions about effects in humans therefore remain tentative.

How should the powder be stored?

Dry powder is commonly held at minus twenty degrees Celsius, desiccated and away from light. Cold storage slows degradation of the lyophilized material.

Network